Document Type

Journal Article

Publication Title

Future oncology (London, England)

Volume

18

Issue

8

First Page

903

Last Page

913

PubMed ID

35073733

Publisher

Future Science Group

School

School of Medical and Health Sciences

Funders

Financial & competing interests disclosure - more details: https://doi.org/10.2217/fon-2021-1286

Comments

Eggermont, A. M., Ascierto, P. A., Khushalani, N. I., Schadendorf, D., Boland, G., Weber, J., ... & Diab, A. (2022). PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology, 18 (8), 903-913. https://doi.org/10.2217/fon-2021-1286

Abstract

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, phase III, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO.

DOI

10.2217/fon-2021-1286

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Diseases Commons

Share

 
COinS